226 related articles for article (PubMed ID: 36263027)
1. Next generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development.
Ahmels M; Mariz FC; Braspenning-Wesch I; Stephan S; Huber B; Schmidt G; Cao R; Müller M; Kirnbauer R; Rösl F; Hasche D
Front Immunol; 2022; 13():1010790. PubMed ID: 36263027
[TBL] [Abstract][Full Text] [Related]
2. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
3. Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).
Huber B; Schellenbacher C; Shafti-Keramat S; Jindra C; Christensen N; Kirnbauer R
PLoS One; 2017; 12(1):e0169533. PubMed ID: 28056100
[TBL] [Abstract][Full Text] [Related]
4. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
5. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses.
Schellenbacher C; Kwak K; Fink D; Shafti-Keramat S; Huber B; Jindra C; Faust H; Dillner J; Roden RBS; Kirnbauer R
J Invest Dermatol; 2013 Dec; 133(12):2706-2713. PubMed ID: 23752042
[TBL] [Abstract][Full Text] [Related]
7. VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus.
Tumban E; Peabody J; Tyler M; Peabody DS; Chackerian B
PLoS One; 2012; 7(11):e49751. PubMed ID: 23185426
[TBL] [Abstract][Full Text] [Related]
8. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2.
Tumban E; Peabody J; Peabody DS; Chackerian B
PLoS One; 2011; 6(8):e23310. PubMed ID: 21858066
[TBL] [Abstract][Full Text] [Related]
9. Expression of different L1 isoforms of
Fu Y; Cao R; Schäfer M; Stephan S; Braspenning-Wesch I; Schmitt L; Bischoff R; Müller M; Schäfer K; Vinzón SE; Rösl F; Hasche D
Elife; 2020 Aug; 9():. PubMed ID: 32746966
[TBL] [Abstract][Full Text] [Related]
10. Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonists.
Zacharia A; Harberts E; Valencia SM; Myers B; Sanders C; Jain A; Larson NR; Middaugh CR; Picking WD; Difilippantonio S; Kirnbauer R; Roden RB; Pinto LA; Shoemaker RH; Ernst RK; Marshall JD
Vaccine; 2021 Jan; 39(2):292-302. PubMed ID: 33309485
[TBL] [Abstract][Full Text] [Related]
11. RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer.
Olczak P; Matsui K; Wong M; Alvarez J; Lambert P; Christensen ND; Hu J; Huber B; Kirnbauer R; Wang JW; Roden RBS
J Virol; 2022 Jul; 96(13):e0056622. PubMed ID: 35703545
[TBL] [Abstract][Full Text] [Related]
12. Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer.
Zhai L; Yadav R; Kunda NK; Anderson D; Bruckner E; Miller EK; Basu R; Muttil P; Tumban E
Antiviral Res; 2019 Jun; 166():56-65. PubMed ID: 30926288
[TBL] [Abstract][Full Text] [Related]
13. Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.
Tyler M; Tumban E; Dziduszko A; Ozbun MA; Peabody DS; Chackerian B
Vaccine; 2014 Jul; 32(34):4267-74. PubMed ID: 24962748
[TBL] [Abstract][Full Text] [Related]
14. Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies.
Combelas N; Saussereau E; Fleury MJ; Ribeiro T; Gaitan J; Duarte-Forero DF; Coursaget P; Touzé A
J Transl Med; 2010 Mar; 8():28. PubMed ID: 20334659
[TBL] [Abstract][Full Text] [Related]
15. Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP.
Valencia SM; Zacharia A; Marin A; Matthews RL; Wu CK; Myers B; Sanders C; Difilippantonio S; Kirnbauer R; Roden RB; Pinto LA; Shoemaker RH; Andrianov AK; Marshall JD
Hum Vaccin Immunother; 2021 Aug; 17(8):2748-2761. PubMed ID: 33573433
[TBL] [Abstract][Full Text] [Related]
16. A three component mix of thioredoxin-L2 antigens elicits broadly neutralizing responses against oncogenic human papillomaviruses.
Seitz H; Canali E; Ribeiro-Müller L; Pàlfi A; Bolchi A; Tommasino M; Ottonello S; Müller M
Vaccine; 2014 May; 32(22):2610-7. PubMed ID: 24662712
[TBL] [Abstract][Full Text] [Related]
17. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
Jagu S; Karanam B; Gambhira R; Chivukula SV; Chaganti RJ; Lowy DR; Schiller JT; Roden RB
J Natl Cancer Inst; 2009 Jun; 101(11):782-92. PubMed ID: 19470949
[TBL] [Abstract][Full Text] [Related]
18. Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?
Yadav R; Zhai L; Tumban E
Viruses; 2019 Dec; 12(1):. PubMed ID: 31877975
[TBL] [Abstract][Full Text] [Related]
19. A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9.
Zhai L; Peabody J; Pang YS; Schiller J; Chackerian B; Tumban E
Antiviral Res; 2017 Nov; 147():116-123. PubMed ID: 28939477
[TBL] [Abstract][Full Text] [Related]
20. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.
Jagu S; Karanam B; Wang JW; Zayed H; Weghofer M; Brendle SA; Balogh KK; Tossi KP; Roden RBS; Christensen ND
Vaccine; 2015 Oct; 33(42):5553-5563. PubMed ID: 26382603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]